Marker Therapeutics, Inc. Common Stock (MRKR) — Analysis Summary
Marker Therapeutics, Inc. Common Stock (MRKR) has a market cap of $16.84M with year-over-year revenue growth of -46.2%. Net margin stands at -343.0%. The stock trades at a P/E ratio of -1.9.
Key Takeaways
- Revenue changed -46.2% year-over-year
- Net margin of -343.0%
- P/E ratio of -1.9
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, MRKR posted revenue growth of -46.2% and trades at a P/E of -1.9.
Marker Therapeutics, Inc. Common Stock (MRKR)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Revenue fell 100.0% vs the prior period.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Sector
PHARMACEUTICAL PREPARATIONS
Employees
5
Headquarters
HOUSTON, TX
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.